皓宸医疗
(002622)
| 流通市值：25.54亿 | | | 总市值：25.54亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 635,030,298.87 | 382,010,234.1 | 163,503,563.1 | 756,709,758.78 |
| 营业收入 | 635,030,298.87 | 382,010,234.1 | 163,503,563.1 | 756,709,758.78 |
| 二、营业总成本 | 630,093,894.86 | 398,227,590.97 | 179,781,974.53 | 732,435,656.95 |
| 营业成本 | 330,407,017.3 | 206,067,242.04 | 88,077,775.6 | 371,344,654.98 |
| 税金及附加 | 1,971,996.36 | 1,228,304.73 | 547,552.85 | 2,290,738.46 |
| 销售费用 | 141,873,589.24 | 89,747,327.44 | 41,887,503.48 | 154,450,891.06 |
| 管理费用 | 115,737,337.12 | 74,914,155.33 | 36,353,366.81 | 142,156,430.9 |
| 研发费用 | 5,583,042.65 | 3,605,476.51 | 1,594,263.46 | 15,897,625.56 |
| 财务费用 | 34,520,912.19 | 22,665,084.92 | 11,321,512.33 | 46,295,315.99 |
| 其中:利息费用 | 32,223,746.81 | 21,454,310.59 | 8,485,924.86 | 44,630,037.8 |
| 其中:利息收入 | 1,088,328.61 | 897,501.49 | 251,066.83 | 1,781,954.92 |
| 加:公允价值变动收益 | - | - | - | 714,184.71 |
| 加:投资收益 | 21,512,603.77 | 16,737,122.44 | 9,359,248.59 | 18,178,250.76 |
| 资产处置收益 | -1,486.97 | - | 145,525.65 | 4,171,003.29 |
| 资产减值损失(新) | -361,829.62 | - | -145,729.27 | -92,371,046.3 |
| 信用减值损失(新) | 1,016,271.72 | 1,849,323.45 | 101,946.44 | -4,433,407.53 |
| 其他收益 | 4,348,332.37 | 1,817,867.61 | 205,821.01 | 6,028,437.23 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 31,450,295.28 | 4,186,956.63 | -6,611,599.01 | -43,438,476.01 |
| 加:营业外收入 | 186,579.91 | 165,728.27 | - | 4,697,844.3 |
| 减:营业外支出 | 334,261.26 | 166,708.68 | 128,293.14 | 15,372,533.26 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,302,613.93 | 4,185,976.22 | -6,739,892.15 | -54,113,164.97 |
| 减:所得税费用 | 2,620,935.63 | 1,379,875.03 | 285,389.17 | 4,146,379.04 |
| 六、净利润 | 28,681,678.3 | 2,806,101.19 | -7,025,281.32 | -58,259,544.01 |
| 持续经营净利润 | 28,681,678.3 | 2,806,101.19 | -7,025,281.32 | -58,259,544.01 |
| 归属于母公司股东的净利润 | 13,496,659.38 | 553,485.18 | -4,572,538.15 | -94,365,092.81 |
| 少数股东损益 | 15,185,018.92 | 2,252,616.01 | -2,452,743.17 | 36,105,548.8 |
| (一)基本每股收益 | 0.02 | 0 | -0.01 | -0.11 |
| (二)稀释每股收益 | 0.02 | 0 | -0.01 | -0.11 |
| 八、其他综合收益 | 1,540,094.91 | 2,010,575.34 | 900,341.54 | -23,036,986.32 |
| 归属于母公司股东的其他综合收益 | 1,540,094.91 | 2,010,575.34 | 900,341.54 | -23,036,986.32 |
| 九、综合收益总额 | 30,221,773.21 | 4,816,676.53 | -6,124,939.78 | -81,296,530.33 |
| 归属于母公司股东的综合收益总额 | 15,036,754.29 | 2,564,060.52 | -3,672,196.61 | -117,402,079.13 |
| 归属于少数股东的综合收益总额 | 15,185,018.92 | 2,252,616.01 | -2,452,743.17 | 36,105,548.8 |
| 公告日期 | 2024-10-31 | 2024-08-30 | 2024-04-29 | 2024-04-29 |
| 审计意见(境内) | | | | 带强调事项段的无保留意见 |